Skip to main content
Back to Blogs

Thinking Zebras: Understanding Neuroendocrine Tumours and Why Early Detection Matters

Thinking Zebras: Understanding Neuroendocrine Tumours and Why Early Detection Matters

In medicine, students are taught a useful heuristic: "When you hear hoofbeats, think horses, not zebras" — meaning look for common explanations before rare ones. Neuroendocrine tumours (NETs) are the zebras of the oncology world. Because their symptoms often closely resemble those of everyday conditions such as irritable bowel syndrome, asthma or anxiety, they are frequently overlooked for years before the correct diagnosis is reached. Increasing awareness of these tumours, their characteristic presentations and the specialised diagnostic tools required to identify them is essential for improving outcomes.

Neuroendocrine cells are distributed throughout the body, occurring in particularly high concentrations in the gastrointestinal tract, pancreas and lungs. These cells serve as an interface between the nervous system and the endocrine system, responding to neural signals by releasing hormones. When they grow abnormally, the resulting tumours are termed neuroendocrine tumours. NETs are a heterogeneous group: some are slow-growing and indolent, others are aggressive and require urgent systemic treatment. This variability makes them challenging to manage and underscores the importance of accurate grading and staging at diagnosis.

Symptoms: Why Neuroendocrine Tumours Are So Frequently Missed

Many NETs are functionally active, meaning they secrete excess hormones or bioactive substances that produce symptoms. The nature of those symptoms depends on what the tumour secretes and where it arises. A carcinoid tumour arising in the small intestine may secrete serotonin and other vasoactive compounds, causing what is known as carcinoid syndrome: episodic flushing of the face and neck (characteristically dry, without sweating), persistent diarrhoea, abdominal cramping and, over time, right-sided valvular heart disease.

The problem is that each of these symptoms, in isolation, points readily towards far more common diagnoses. Persistent diarrhoea is attributed to irritable bowel syndrome; facial flushing to rosacea or perimenopause; wheezing and breathlessness to asthma; fatigue and blood sugar fluctuations to thyroid disease or diabetes. The average time from first symptom to NET diagnosis has historically been five to seven years, a gap that carries real consequences because tumours that are localised at diagnosis are far more amenable to curative treatment than those that have metastasised.

Non-functioning NETs produce no hormonal symptoms and are often discovered incidentally during imaging for an unrelated condition, or only once the tumour has grown large enough to cause mass-effect symptoms such as obstructive jaundice, bowel obstruction or a palpable abdominal mass. These tumours present a different diagnostic challenge: the absence of hormonal clues means their presence is not suggested by the clinical picture at all.

Risk Factors and Who Is Most at Risk

The exact cause of most NETs remains unknown. However, certain inherited genetic syndromes significantly increase risk. Multiple Endocrine Neoplasia type 1 (MEN1) is the most important of these: it predisposes carriers to pancreatic NETs, pituitary tumours and parathyroid hyperplasia, and accounts for a meaningful proportion of pancreatic NET cases. Von Hippel-Lindau syndrome and Neurofibromatosis type 1 are also associated with elevated NET risk.

A family history of neuroendocrine or other endocrine cancers warrants discussion with a specialist, as does a personal history of chronic atrophic gastritis, which creates the hypergastrinaemia that can drive the proliferation of enterochromaffin-like cells in the stomach lining and lead to type 1 gastric NETs. For most patients without these risk factors, however, NETs arise sporadically and without a clear preceding cause, reinforcing the importance of maintaining a high index of suspicion when symptoms fail to respond to standard treatment for more common diagnoses.

Modern Diagnostic Approaches: Specialised Tools for a Difficult Diagnosis

Because NETs are often small and because standard cross-sectional imaging (CT or MRI) can miss them entirely, a specialised diagnostic approach is required. Biochemical testing plays an important role: serum Chromogranin A (CgA) is a general NET marker elevated in the majority of functioning and non-functioning tumours, while 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) is a specific marker for carcinoid syndrome, reflecting serotonin metabolism. These tests are not diagnostic in isolation but provide supportive evidence and are valuable for monitoring treatment response.

The most significant advance in NET imaging has been the Gallium-68 DOTATATE PET/CT scan. The majority of NETs overexpress somatostatin receptors on their cell surfaces; the DOTATATE ligand binds selectively to these receptors, and when labelled with the positron-emitting isotope Gallium-68, it allows functional imaging of NETs with far greater sensitivity than conventional CT or MRI. Ga-68 DOTATATE PET/CT can detect primary tumours, nodal involvement and distant metastases, including liver metastases that are occult on standard imaging, transforming both staging accuracy and treatment planning.

Tissue diagnosis remains essential. Endoscopy with biopsy, or image-guided biopsy of accessible lesions, provides material for histological grading. The Ki-67 proliferation index is central to grading: grade 1 (Ki-67 under 3%) and grade 2 (Ki-67 3-20%) tumours are classified as well-differentiated NETs and generally follow a more indolent course, while grade 3 neuroendocrine carcinomas (Ki-67 over 20%) are poorly differentiated, aggressive and require a different treatment strategy entirely.

Advances in Treatment: More Options and More Hope Than Ever Before

Surgery remains the primary curative approach for localised NETs and, in selected cases with limited hepatic metastases, can also be considered in the metastatic setting. For functioning tumours producing symptomatic hormonal excess, somatostatin analogues (SSAs) such as octreotide and lanreotide are foundational: administered as monthly depot injections, they bind to somatostatin receptors on NET cells, suppressing hormone secretion and providing both symptom control and anti-proliferative benefit. The PROMID and CLARINET trials established SSAs as a standard of care for progressive well-differentiated NETs.

The most significant recent advance in NET therapy is Peptide Receptor Radionuclide Therapy (PRRT), specifically Lutetium-177 DOTATATE. Building on the same somatostatin receptor targeting used in Ga-68 PET imaging, PRRT delivers beta-emitting radiation directly to tumour cells via the DOTATATE ligand while largely sparing surrounding healthy tissue. The NETTER-1 trial demonstrated a highly significant improvement in progression-free survival with Lutetium-177 DOTATATE compared to high-dose octreotide in patients with advanced midgut NETs, and the treatment is now used across NET subtypes in specialist centres.

Targeted therapies provide further options. Everolimus (an mTOR inhibitor) has demonstrated efficacy in pancreatic NETs and in non-functional gastrointestinal and lung NETs, while sunitinib (a multi-kinase inhibitor) is approved for progressive pancreatic NETs. Liver-directed therapies including transarterial chemoembolisation (TACE) and selective internal radiation therapy (SIRT) are used for patients with predominantly hepatic disease burden. The NET treatment landscape has changed profoundly in the past decade, and patients who present with a new diagnosis today have access to a range of effective, targeted options that were not available to earlier generations, making timely, accurate diagnosis more consequential and more rewarding than ever before.

Written by: Dr. Swaroop Revannasiddaiah, MBBS, MD (Radiotherapy and Clinical Oncology), DM (Medical Oncology), MRCP (Medical Oncology, Royal College of Physicians, UK), Thoracic Oncology Certification (University of Michigan, USA), ESMO Certification, Executive MBA (University of Nicosia), Senior Consultant, Medical Oncology, NiSH Clinic, Jayanagar, Bengaluru.

Related reading: linqmd.com/doctor/swaroop-r/blog/neuroendocrine-tumours-nets-symptoms-diagnosis-treatment-bengaluru

Dr. Swaroop Revannasiddaiah

About the Author

Dr. Swaroop Revannasiddaiah

Senior Consultant - Medical Oncology

12+ Years of Excellence 15,000+ Patients cared


Add a Comment